Newsroom Articles

Ionis has been recognized as one of the San Diego Business Journal's Best Places to Work for the third consecutive year. This year, Ionis ranked #3 in the Large Company category, climbing three spots from #6 in 2025.

Explore Ionis' 2025 Corporate Responsibility Report — covering RNA-targeted medicine breakthroughs, ESG commitments, employee impact, and sustainability milestones.

2025 was a defining year for Ionis, hallmarked by our first two independent launches as a commercial stage biotech company. Now, Ionis is poised for another transformative year - at JPM 2026 we shared highlights from the past year and outlined key anticipated milestones.

Recognizing our industry-leading scientific innovation and company culture, Science magazine ranked Ionis their #2 Top Employer in 2025.

In celebration of Brett Monia, Ph.D., recipient of the 2025 Oligonucleotide Therapeutics Society (OTS) Lifetime Achievement Award, colleagues and peers reflect on his extraordinary impact on science, leadership and patient care.

Endpoints News honors Ionis’ Holly Kordasiewicz, Ph.D., SVP, Neurology for her leadership, scientific impact and commitment to advancing diversity in biopharma

Ionis is proud to announce that we have ranked #6 on the San Diego Business Journal’s 2025 Best Places to Work list in the Large Companies category. This marks our second consecutive year being recognized and our first year breaking into the Top 10…

Each year, the Family Heart Foundation, a patient-advocacy organization dedicated to increasing early diagnosis and treatment of lipoprotein(a) and familial hypercholesterolemia, recognizes individuals whose contributions have reshaped…

Ionis CEO Brett Monia, Ph.D. shares the journey to becoming a fully integrated biotech, advancing RNA-targeted medicines and delivering greater impact for patients.